Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting

  1. Müller, Lisa ORCID logo
  2. Ostermann, Philipp Niklas ORCID logo
  3. Walker, Andreas
  4. Wienemann, Tobias
  5. Mertens, Alexander
  6. Adams, Ortwin
  7. Andree, Marcel
  8. Hauka, Sandra
  9. Lübke, Nadine
  10. Keitel, Verena
  11. Drexler, Ingo
  12. Di Cristanziano, Veronica
  13. Hermsen, Derik Franz
  14. Kaiser, Rolf
  15. Boege, Friedrich
  16. Klein, Florian
  17. Schaal, Heiner ORCID logo
  18. Timm, Joerg ORCID logo
  19. Senff, Tina ORCID logo

Download
s10096-021-04169-7.pdf 591,89KB
WeightNameValue
1000 Titel
  • Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting
1000 Autor/in
  1. Müller, Lisa |
  2. Ostermann, Philipp Niklas |
  3. Walker, Andreas |
  4. Wienemann, Tobias |
  5. Mertens, Alexander |
  6. Adams, Ortwin |
  7. Andree, Marcel |
  8. Hauka, Sandra |
  9. Lübke, Nadine |
  10. Keitel, Verena |
  11. Drexler, Ingo |
  12. Di Cristanziano, Veronica |
  13. Hermsen, Derik Franz |
  14. Kaiser, Rolf |
  15. Boege, Friedrich |
  16. Klein, Florian |
  17. Schaal, Heiner |
  18. Timm, Joerg |
  19. Senff, Tina |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-03
1000 Erschienen in
1000 Quellenangabe
  • 40(5):1063-1071
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10096-021-04169-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856849/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Evaluation and power of seroprevalence studies depend on the performed serological assays. The aim of this study was to assess four commercial serological tests from EUROIMMUN, DiaSorin, Abbott, and Roche as well as an in-house immunofluorescence and neutralization test for their capability to identify SARS-CoV-2 seropositive individuals in a high-prevalence setting. Therefore, 42 social and working contacts of a German super-spreader were tested. Consistent with a high-prevalence setting, 26 of 42 were SARS-CoV-2 seropositive by neutralization test (NT), and immunofluorescence test (IFT) confirmed 23 of these 26 positive test results (NT 61.9% and IFT 54.8% seroprevalence). Four commercial assays detected anti-SARS-CoV-2 antibodies in 33.3-40.5% individuals. Besides an overall discrepancy between the NT and the commercial assays regarding their sensitivity, this study revealed that commercial SARS-CoV-2 spike-based assays are better to predict the neutralization titer than nucleoprotein-based assays are.
1000 Sacherschließung
lokal Contact Tracing [MeSH]
gnd 1206347392 COVID-19
lokal Aged [MeSH]
lokal Seroprevalence
lokal Antibodies, Neutralizing/blood [MeSH]
lokal COVID-19 Serological Testing/methods [MeSH]
lokal Original Article
lokal SARS-CoV-2/isolation
lokal Sensitivity and Specificity [MeSH]
lokal Male [MeSH]
lokal SARS-CoV-2/immunology [MeSH]
lokal COVID-19 Serological Testing/standards [MeSH]
lokal Neutralizing antibodies
lokal Prevalence [MeSH]
lokal COVID-19/epidemiology [MeSH]
lokal SARS-CoV-2
lokal COVID-19/diagnosis [MeSH]
lokal Antibodies, Viral/blood [MeSH]
lokal Serology
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Neutralization Tests [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Middle Aged [MeSH]
lokal COVID-19
lokal Immunofluorescence test
lokal Young Adult [MeSH]
lokal COVID-19/blood [MeSH]
lokal Immunoassay [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-0728-0012|https://orcid.org/0000-0002-4419-6119|https://frl.publisso.de/adhoc/uri/V2Fsa2VyLCBBbmRyZWFz|https://frl.publisso.de/adhoc/uri/V2llbmVtYW5uLCBUb2JpYXM=|https://frl.publisso.de/adhoc/uri/TWVydGVucywgQWxleGFuZGVy|https://frl.publisso.de/adhoc/uri/QWRhbXMsIE9ydHdpbg==|https://frl.publisso.de/adhoc/uri/QW5kcmVlLCBNYXJjZWw=|https://frl.publisso.de/adhoc/uri/SGF1a2EsIFNhbmRyYQ==|https://frl.publisso.de/adhoc/uri/TMO8YmtlLCBOYWRpbmU=|https://frl.publisso.de/adhoc/uri/S2VpdGVsLCBWZXJlbmE=|https://frl.publisso.de/adhoc/uri/RHJleGxlciwgSW5nbw==|https://frl.publisso.de/adhoc/uri/RGkgQ3Jpc3RhbnppYW5vLCBWZXJvbmljYQ==|https://frl.publisso.de/adhoc/uri/SGVybXNlbiwgRGVyaWsgRnJhbno=|https://frl.publisso.de/adhoc/uri/S2Fpc2VyLCBSb2xm|https://frl.publisso.de/adhoc/uri/Qm9lZ2UsIEZyaWVkcmljaA==|https://frl.publisso.de/adhoc/uri/S2xlaW4sIEZsb3JpYW4=|https://orcid.org/0000-0002-1636-4365|https://orcid.org/0000-0001-7799-3045|https://orcid.org/0000-0003-1578-8163
1000 Hinweis
  • DeepGreen-ID: 73e0c3c8c21243a486c04ca33504e222 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6448977.rdf
1000 Erstellt am 2023-05-04T10:55:21.752+0200
1000 Erstellt von 322
1000 beschreibt frl:6448977
1000 Zuletzt bearbeitet 2023-10-21T00:05:36.850+0200
1000 Objekt bearb. Sat Oct 21 00:05:36 CEST 2023
1000 Vgl. frl:6448977
1000 Oai Id
  1. oai:frl.publisso.de:frl:6448977 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source